ClinicalTrials.gg
Active, not recruitingNCT06732583Updated Apr 30, 2026

A Study to Evaluate the Safety and Immunogenicity of Ad5-105K in Adults Aged 18 to 49 Years

A Phase 1 interventional study of Tuberculosis (TB) vaccine (Ad5-105K) and Placebo in Tuberculosis, sponsored by CanSino Biologics Inc.. Active, not recruiting at 1 site in Indonesia. Open to participants aged 18 Years to 49 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-30.

Sponsored by CanSino Biologics Inc. · Phase 1, Interventional, and Prevention

How we know

From the registry’s dates

  • Primary completion was expected by Aug 2026, 3 months ago, but the record still lists the study as active, not recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
18 Years to 49 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 37 studies in Tuberculosis with a site in Indonesia — 8 open to participants now, 13 under way, 3 of them phase 3. Tuberculosis · Indonesia.

Enrollment
27th of 34
36 · median 92
Started
2025
with 4 others
Phase 1
3 of 37
1 open now
Primary completion
2026-08
later than 5 of 12 live
Registered
28th of 37
by date
Lead sponsor
1 of 37
CanSino Biologics Inc.

Among the 37 studies in Tuberculosis with a site in Indonesia, this one is the 27th largest by enrollment of the 34 interventional ones that give a count, is one of 5 that started in 2025, is one of 3 in phase 1, reaches primary completion later than 5 of the 12 other live ones, and was the 28th registered.

Tuberculosis

1,171 studies on the registry are indexed under Tuberculosis; 176 are open to participants now.

Browse Tuberculosis studies →

Open to participants now

8 of the 37 studies in Tuberculosis with a site in Indonesia are open now. Recruiting first, the newest first:

3 more — sign in →

All 8 open studies →

A study can be open while its sites in Indonesia have not opened yet or have stopped. Only those recruiting at a site in Indonesia →

Who these studies take

Of the 112 Tuberculosis studies recruiting now, 65 (58%) set no upper age limit and 37 (33%) stop at 75 or younger; 49 take children under 18; 31 take healthy volunteers.

This study: 18 Years to 49 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 37 studies in Tuberculosis with a site in Indonesia, or all of them as a file.
02

Study summary

This is a randomized, observer-blind, positive-controlled study. There will be 2 treatment groups (Group A and B). In each treatment group, 18 participants will be randomly assigned to receive either the investigational vaccine (Dose A or Dose B of Ad5-105K) or a placebo in a ratio of 2:1. The distribution of participant's gender and age should be balanced in each group.

03

Conditions studied

  • Tuberculosis

Browse trials for

Keywords

  • Vaccine
  • Ad5-105K
  • Immunogenicity
  • Safety
  • 18-49 years
  • TB
04

Who can participate

Ages eligible
18 Years to 49 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants who, in the opinion of the investigator, are able and willing to comply with the requirements of the protocol (e.g., completion of diary cards, returning for follow-up visits).
  • Healthy male or female participants aged 18 to 49 years, at the time of obtaining .
  • Written (or thumb printed and witnessed) informed consent obtained from the participant.
  • Positive IGRA test with no history of TB disease or treatment.
  • Female participants of must have a negative urine pregnancy test at screening and on the day of vaccination. Male and female participants of childbearing potential must agree to use adequate for the entire duration of their participation in the study.
  • History of BCG vaccination.

Exclusion criteria

Exclusion Criteria:

  • Current TB disease, or a history of TB disease and/or treatment for TB (including Tuberculosis Preventive Therapy (TPT)).
  • Known history of close or household contact with active TB patient.
  • Axillary temperature ≥37.5°C.
  • Presence of congenital malformations or developmental disorders, genetic defects, severe malnutrition, etc.
  • Lactating women.
  • Individuals who smoke more than 10 cigarettes per day within the last 3 months and/or more than 2 cigars per day, and/or vapers who use more than 5 ml of e-liquid daily.
  • Individuals with positive , , , or TP (Treponema pallidum) test.
  • History of treatment, cytotoxic treatment, or treatment, etc. (excluding local treatments, surface treatments for acute non-concurrent dermatitis or spray treatment for allergic rhinitis) in the past 6 months (internal time \<6 months).
  • History of, or plans to use, blood/plasma products or immunoglobulins within 60 days prior to study vaccination or at any time during the study period.
  • Uncontrolled severe hypertension (at the time of field measurement: systolic blood pressure ≥160 mmHg and diastolic blood pressure ≥100 mmHg).
  • Suffering from a serious chronic disease or a condition that is in a progressive stage and cannot be adequately controlled (e.g., thyroid disease), or having known or suspected diseases that at investigators' discretion, may affect vaccination or immunogenicity test results (e.g., diagnosed with asthma within the last 20 years, severe respiratory disease, acute infection or active chronic disease, severe cardiovascular disease, severe liver or kidney disease, , severe infectious or allergic skin disease).
  • History of serious adverse reactions associated with the adenovirus vector-based vaccine and/or history of severe allergic reactions (e.g., systemic allergic reactions) to any component of the study vaccine.
  • Immunocompromised individuals with known or suspected immunodeficiency as determined by medical history and/or physical examination (e.g., HIV infection, or a history of pancreatic, liver, spleen, kidney disease, or a history of organ resection).
  • Bleeding constitution or condition associated with prolonged bleeding for which IM injection is , in the opinion of the investigator.
  • History of administration of any vaccine within the past three months.
  • History of receiving experimental Mycobacterium tuberculosis (Mtb) vaccines or participation in other interventional studies within 28 days prior to screening and/or during study participation.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 1
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    Experimental vaccine group, Low dose

    1 doses of Ad5-105K vaccine (0.1ml) on Day 0

    Biological: Tuberculosis (TB) vaccine (Ad5-105K)

  • Placebo comparator
    Placebo Group, Low dose

    1 doses of placebo (0.1ml) on Day 0

    Biological: Placebo

  • Active comparator
    Experimental vaccine group, High dose

    1 doses of Ad5-105K vaccine (0.2ml) on Day 0

    Biological: Ad5-105K

  • Placebo comparator
    Placebo Group, High dose

    1 doses of placebo (0.2ml) on Day 0

    Biological: Placebo

Interventions

  • BiologicalTuberculosis (TB) vaccine (Ad5-105K)

    1 doses of Ad5-105K vaccine (1 x 10\^8 vp)) on Day 0, Nebulized Inhalation (IH) through mouth

  • BiologicalPlacebo

    1 doses of placebo on Day 0, IH

  • BiologicalAd5-105K

    1 doses of Ad5-105K vaccine (2 x 10\^8 vp)) on Day 0, IH

  • BiologicalPlacebo

    1 doses of placebo on Day 0, IH

06

What researchers measure

Primary outcomes

  1. Occurrence of solicited adverse events (AEs)

    Time frame: Within 7 days after vaccination

Secondary outcomes

  1. Occurrence of solicited AEs

    Time frame: Within 30 mins after vaccination

  2. Occurrence of unsolicited AEs

    Time frame: Within 28 days after vaccination

  3. Occurrence of serious adverse events (SAEs) and adverse events of special interest (AESI)

    Time frame: Through study completion, an average of 6 months

  4. Occurrence of abnormal hematology and chemistry laboratory assessments

    Time frame: On Day 3 after vaccination

  5. Geometric mean titer (GMT) of anti-TB75K and anti-Ag85A IgG antibodies before vaccination

    Time frame: On Day 14 and Day 28 post-vaccination

  6. Expression level of IFN-γ, TNF-α, IL-2, and IL-17 in 105K specific CD4+/CD8+ T cells evaluated by ICS

    Time frame: Before vaccination and on Day 14 and Day 28 post-vaccination

07

Study locations

1 site
  • Rumah Sakit Islam Jakarta Cempaka Putih
    Jakarta, Indonesia
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for Aug 2026, 9 months after the start.

Of 60 phase 1 interventional studies under Tuberculosis, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 25. This study's planned 9 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 10, 2024
First posted
Dec 13, 2024
StartActual
Nov 13, 2025
Primary completionEst.
Aug 2026
CompletionEst.
Aug 2026
Last update
Apr 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06732583
Collaborators
PT Etana Biotechnologies Indonesia
Responsible party
Sponsor
First posted
Dec 13, 2024
Start date
Nov 13, 2025
Primary completion
Aug 2026 (estimated)
Completion
Aug 2026 (estimated)
Last update
Apr 30, 2026

Study contacts

Erlina Burhan
principal investigator · Respiratory Programmatic Implementation and Research Institute & RSUP Persahabatan

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion